- Home
- TGE vs CRVS Comparison
TGE vs CRVS Comparison
Compare TGE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGE
- CRVS
- Stock Information
- Founded
- TGE 2023
- CRVS 2014
- Country
- TGE France
- CRVS United States
- Employees
- TGE N/A
- CRVS N/A
- Industry
- TGE Newspapers/Magazines
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TGE Consumer Discretionary
- CRVS Health Care
- Exchange
- TGE Nasdaq
- CRVS Nasdaq
- Market Cap
- TGE 290.8M
- CRVS 305.4M
- IPO Year
- TGE N/A
- CRVS 2016
- Fundamental
- Price
- TGE $5.29
- CRVS $4.10
- Analyst Decision
- TGE
- CRVS Strong Buy
- Analyst Count
- TGE 0
- CRVS 4
- Target Price
- TGE N/A
- CRVS $15.00
- AVG Volume (30 Days)
- TGE 58.0K
- CRVS 445.0K
- Earning Date
- TGE 01-01-0001
- CRVS 08-12-2025
- Dividend Yield
- TGE N/A
- CRVS N/A
- EPS Growth
- TGE N/A
- CRVS N/A
- EPS
- TGE 1.64
- CRVS N/A
- Revenue
- TGE $77,014,000.00
- CRVS N/A
- Revenue This Year
- TGE N/A
- CRVS N/A
- Revenue Next Year
- TGE N/A
- CRVS N/A
- P/E Ratio
- TGE $3.37
- CRVS N/A
- Revenue Growth
- TGE 81.03
- CRVS N/A
- 52 Week Low
- TGE $5.23
- CRVS $2.47
- 52 Week High
- TGE $37.02
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TGE N/A
- CRVS 44.93
- Support Level
- TGE N/A
- CRVS $4.58
- Resistance Level
- TGE N/A
- CRVS $4.98
- Average True Range (ATR)
- TGE 0.00
- CRVS 0.23
- MACD
- TGE 0.00
- CRVS -0.04
- Stochastic Oscillator
- TGE 0.00
- CRVS 13.79
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).